Seguridad de la ivermectina: toxicidad y reacciones adversas en diversas especies de mamíferos

Contenido principal del artículo

Autores

Aránzazu González-Canga Nélida Fernández-Martínez Ana Sahagún-Prieto Juan García-Vieitez María Díez Pedro Tamame-Martín Matilde Sierra-Vega

Resumen

La ivermectina es un fármaco antiparasitario muy utilizado en Medicina Veterinaria, dado su espectro de actividad que abarca tanto endo como ectoparásitos, elevada eficacia y amplio margen de seguridad. No obstante, su administración puede dar lugar a efectos tóxicos. La mayoría de ellos derivan de la sobredosificación del compuesto, aunque también se han descrito, a dosis terapéuticas, casos de susceptibilidad extrema a los efectos neurotóxicos del fármaco en determinadas razas o subpoblaciones de animales, así como reacciones anafilácticas por la destrucción masiva de parásitos.

Palabras clave:

Detalles del artículo

Referencias

1. McKellar QA, Benchaoui HA. Avermectins and milbemycins. J Vet Pharmacol Ther 1996; 19: 331-351. http://dx.doi.org/10.1111/j.1365-2885.1996.tb00062.x

2. Burkhart CN. Ivermectin: an assessment of its Pharmacology, Microbiology and safety. Vet Hum Toxicol 2000; 42: 30- 35.

3. Lankas GR, Gordon LR. Toxicology. En: Campbell WC, ed. Ivermectin and abamectin. New York: Springer-Verlag; 1989: 89-112.

4. Marques-Santos LF, Bernardo RR, Paula E, Rumjanek VM. Cyclosporin A and trifluoperazine, two resistancemodulating agents, increase ivermectin neurotoxicity in mice. Pharmacol Toxicol 1999; 84: 125-129. http://dx.doi.org/10.1111/j.1600-0773.1999.tb00887.x

5. Dadarkar SS, Deore MD, Gatne MM. Comparative evaluation of acute toxicity of ivermectin by two methods after single subcutaneous administration in rats. Regul Toxicol Pharmacol 2007; 47: 257-260. http://dx.doi.org/10.1016/j.yrtph.2006.10.009

6. Schinkel AH, Smit JJM, Van Telligen O, Beijnen JH, Wagenaar E, Van Deemter L, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood brain barrier and to increased sensivity to drugs. Cell 1994; 77: 491-502. http://dx.doi.org/10.1016/0092-8674(94)90212-7

7. Schinkel AH, Wagenaar E, Van Deemter L, Mol CA, Borst P. Absence of mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethason, digoxin and ciclosporyn A. J Clin Invest 1995; 96: 1698-1705. http://dx.doi.org/10.1172/JCI118214

8. Lankas GR, Cartwright ME, Umbenhauer DR. P-glycoprotein deficiency in a subpopulation of mice enhances avermectin-induced neurotoxicity. Toxicol Appl Pharmacol 1997; 143: 357- 365. http://dx.doi.org/10.1006/taap.1996.8086

9. Umbenhauer DR, Lankas GR, Pippert TR, Wise LD, Cartwright ME, Hall SJ, et al. Identification of a P-glycoproteindeficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism. Tox Appl Pharm 1997; 146: 88-94. http://dx.doi.org/10.1006/taap.1997.8225

10. Kwei GY, Alvaro RF, Chen Q, Jenkins HJ, Hop CE, Keohane CA, et al. Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein. Drug Metab Dispos 1999; 27: 581-587.

11. Leaning WHD, Roncalli RA, Brokken ES. The efficacy and safety evaluation of ivermectin: a new injectable antiparasitic agent for cattle. En: Leaning W, Siegmund O, Fraser C, eds. Recent developments in the control of animal parasites. Proceedings of the MSD AGVET Symposium at the XXII World Veterinary Congress. Perth: MSD AGVET; 1983: 25-41.

12. Hotson IK. The development of ivermectin as an antiparasitic agent in sheep. En: Leaning W, Siegmund O, Fraser C, eds. Recent developments in the control of animal parasites. Proceedings of the MSD AGVET Symposium at the XXII World Veterinary Congress. Perth: MSD AGVET; 1983: 42-48.

13. Njanja JC, Bell JF, Wescott RB. Apparent lack of toxicity in adult East African goats on parenterally administered ivermectin. Bull Anim Health Prod Afr 1985; 33: 123-127.

14. Dieterich RA, Craigmill AL. Safety, efficacy, and tissues residues of ivermectin in reindeer. Rangifer 1990; 10: 53-56. http://dx.doi.org/10.7557/2.10.2.794

15. Pulliam JD, Preston JM. Safety of ivermectin in target animals. En: Campbell WC, ed. Ivermectin and abamectin. New York: Springer-Verlag; 1989: 149-161.

16. Leaning WHD. The efficacy and safety evaluation of ivermectin as a parenteral and oral antiparasitic agent in horses. En: Milne FJ, ed. Proceedings of the 29th Annual Convention of the American Association of Equine Practitioners. Las Vegas: American Association of Equine Practitioners; 1983: 319-328.

17. Hautekeete LA, Khan SA, Hales WS. Ivermectin toxicosis in a zebra. Vet Human Toxicol 1998; 40: 29-31.

18. Swor TM, Whittenburg JL, Chaffin MK. Ivermectin toxicosis in three adult horses. J Am Vet Med Assoc 2009; 235: 558-562. http://dx.doi.org/10.2460/javma.235.5.558

19. Hopkins KD, Marcella KL, Strecker AE. Ivermectin toxicosis in a dog. J Am Vet Med Assoc 1990; 197: 93-94.

20. Paul AJ, Tranquilli WJ, Seward RL, Todd KS, DiPietro JA. Clinical observations in Collies given ivermectin orally. Am J Vet Res 1987; 48: 684-685.

21. Tranquilli WJ, Paul AJ, Seward RL. Ivermectin plasma concentration in Collies susceptible to ivermectin induced toxicosis. Am J Vet Res 1989; 50: 769- 770.

22. Rohrer SP, Evans DV. Binding characteristics of ivermectin in plasma from Collie dogs. Vet Res Commun 1990; 14: 157-165.

23. Pulliam JD, Seward RL, Henry RT, Steinberg SA. Investigating ivermectin toxicity in Collies. Vet Med 1985; 80: 33-40.

24. Mealey KL, Bentjen SA, Gay JM, Cantor GH. Ivermectin sensitivity in Collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 2001; 11: 727-733. http://dx.doi.org/10.1097/00008571-200111000-00012

25. Roulet A, Puel O, Gesta S, Lepage JF, Drag M, Soll M, et al. MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. Eur J Pharmacol 2003; 460: 85-91. http://dx.doi.org/10.1016/S0014-2999(02)02955-2

26. Mealey KL, Bentjen SA, Waiting DK. Frequency of the mutant MDR1 allele associated with ivermectin sensitivity in a sample population of Collies from the Northwestern United States. Am J Vet Res 2002; 63: 479-481. http://dx.doi.org/10.2460/ajvr.2002.63.479

27. Hugnet C, Bentjen SA, Mealey KL. Frequency of the mutant MDR1 allele associated with multidrug sensitivity in a sample of Collies from France. J Vet Pharmacol Ther 2004; 27: 227-229. http://dx.doi.org/10.1111/j.1365-2885.2004.00585.x

28. Houston DM, Parent J, Matushek KJ. Ivermectin toxicosis in a dog. J Am Vet Med Assoc 1987; 191: 78-80.

29. Hadrick MK, Bunch SE, Kornegay JN. Ivermectin toxicosis in two Australian shepherds. J Am Vet Med Assoc 1995; 206: 1147-1152.

30. Geyer J, Döring B, Godoy JR, Leidolf R, Moritz A, Petzinger E. Frequency of the nt230 (del4) MDR1 mutation in Collies and related dog breeds in Germany. J Vet Pharmacol Ther 2005; 28: 545-551. http://dx.doi.org/10.1111/j.1365-2885.2005.00692.x

31. Kawabata A, Momoi Y, Inoue-Murayama M, Iwasaki T. Canine MDR1 gene mutation in Japan. J Vet Med Sci 2005; 67: 1103-1107. http://dx.doi.org/10.1292/jvms.67.1103

32. Mealey KL, Munyard KA, Bentjen SA. Frequency of the mutant MDR1 allele associated with multidrug sensitivity in a sample of herding breed dogs living in Australia. Vet Parasitol 2005; 131: 193- 196. http://dx.doi.org/10.1016/j.vetpar.2005.05.004

33. Neff MW, Robertson KR, Wong AK, Safra N, Broman KW, Slatkin M, et al. Breed distribution and history of canine MDR1- 1 Delta, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage. Proc Natl Acad Sci USA 2004; 101: 11725-11730. http://dx.doi.org/10.1073/pnas.0402374101

34. Campbell WC. Use of ivermectin in dogs and cats. En: Campbell WC, ed. Ivermectin and abamectin. New York: Springer-Verlag; 1989: 245-259.

35. Lewis DT, Merchant SR, Neer TM. Ivermectin toxicosis in a kitten. J Am Vet Med Assoc 1994; 205: 584-586.

36. Muhammad G, Abdul J, Khan MZ, Saqib M. Use of neostigmine in massive ivermectin toxicity in cats. Vet Hum Toxicol 2004; 46: 28-29.

37. Lankas GR, Wise LD, Cartwright ME, Pippert T, Umbenhauer DR. Placental Pglycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod Toxicol 1998; 12: 457-463. http://dx.doi.org/10.1016/S0890-6238(98)00027-6

38. Lankas GR, Minsker DH, Robertson RT. Effects of ivermectin on reproduction and neonatal toxicity in rats. Food Chem Toxicol 1989; 27: 523-529. http://dx.doi.org/10.1016/0278-6915(89)90048-3

39. El-Nahas AF, El-Ashmawy IM. Effect of ivermectin on male fertility and its interaction with P-glicoproteína inhibitor (verapamil) in rats. Environ Toxicol Pharmacol 2008; 26 : 206-211. http://dx.doi.org/10.1016/j.etap.2008.03.011

40. El-Ashmawy IM, Mandour AA. Studies on the influence of ivermectin on reproductive organs and liver function in male rabbits. En: Third Vet Med Conf. Zagazig: Egypt; 1996.

41. Brokken ES, Barth D, Foster AG, Pulliam JD, Wallace DH. Ivermectin: a new broad-spectrum antiparasitic agent for swine. En: Leaning W, Siegmund O, Fraser C, eds. Recent developments in the control of animal parasites. Proceedings of the MSD AGVET Symposium at the XXII World Veterinary Congress. Perth: MSD AGVET; 1983: 239-258.

42. McKissick GE, Sutherland IH, Foix J, Olson G. The safety of ivermectin administered orally to pregnant mares. Equine Vet J 1987; 7: 357-367. http://dx.doi.org/10.1016/S0737-0806(87)80006-0

43. Daurio CP, Gilman MR, Pulliam JD, Seward RL. Reproductive evaluation of male Beagle dogs and the safety of ivermectin. Am J Vet Res 1987; 48: 1755-1760.

44. Tanyildizi, S, Bozkurt T. An investigation of the effects of ivermectin on blood serum, semen hyaluronidase activities and spermatological characteristics in sheep. Turk J Vet Anim Sci 2002; 26: 353-357.

45. Schröder J, Swan GE, Barrick RA, Pulliam JD. Effect of ivermectin on the reproductive potential of breeding rams. J S Afr Vet Assoc 1986; 57: 211-213.

46. Janett F, Thun R, Ryhiner A, Burger D, Hassig M, Hertzberg H. Influence of Eqvalan® (ivermectin) on quality and freezability of stallion semen. Theriogenology 2001; 55: 785-792. http://dx.doi.org/10.1016/S0093-691X(01)00443-5

47. Campbell WC, Benz GW. Ivermectin: a review of efficacy and safety. J Vet Pharmacol Ther 1984; 7: 1-16. http://dx.doi.org/10.1111/j.1365-2885.1984.tb00872.x

48. Herd RP, Donham JC. Efficacy of ivermectin against Onchocerca cervicalis microfilarial dermatitis in horses. Am J Vet Res 1983; 44: 1102-1105.

49. Karns PA, Luther DG. A survey of adverse effects associated with ivermectin use in Louisiana horses. J Am Vet Med Assoc 1984; 185: 782-783.

50. Campbell WC, Leaning WHD, Seward RL. Use of ivermectin in horses. En: Campbell WC, ed. Ivermectin and abamectin. New York: Springer-Verlag; 1989: 234-244.

51. Breukink HJ, Eysker M. Intravenous administration of Ivomec® in horses. Tijdschr Diergeneeskd 1995; 120: 113- 114.

Descargas

La descarga de datos todavía no está disponible.